Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward
California
94545
United States
Tel: 510-694-6000
Website: http://www.arcusbio.com/
Email: jobs@arcusbio.com
About Arcus Biosciences, Inc.
Arcus was founded in 2015 with the vision of bringing together scientists, physicians, advisors, and other leaders with significant content-matter expertise to focus on developing highly-combinable, best-in-class cancer therapies. The complexity of the tumor microenvironment requires a deep scientific understanding to guide judicious combinations of therapeutic agents with potential synergistic activity and the ability to identify biomarkers to select patients most likely to achieve significant, durable responses to treatment. Since our inception, our focus has primarily been targeting well-understood biological pathways where the biology had not yet yielded high-quality medicines.
One of Arcus's early key competitive advantages was building a strong foundation of an industry-leading group of individuals who run our world-class discovery engine and development organization. We believe discovery is not a commodity and have invested in building a high-performing research organization. Through the efforts of our discovery and development teams, we were able to bring our first molecule in the clinic from concept to the clinical stage development in less than 21 months.
We have complemented our productive discovery organization with clinical and commercial leadership that has led multiple cancer immunotherapy programs from early-stage development though to successful global launches. As Arcus advances its product candidates through clinical studies, we work closely with the medical community, patients and caregivers to facilitate participation in our clinical trials enabling potential breakthrough medicines to reach patients faster.
Today, with four product candidates in the clinic across more than a dozen clinical studies in areas of high unmet need, we are well on our way to becoming a fully integrated biopharmaceutical company creating best-in-class cancer therapies.
Stock Symbol: RCUS
Stock Exchange: NYSE
107 articles with Arcus Biosciences, Inc.
-
Arcus Biosciences Announces New Employment Inducement Grants - June 09, 2021
6/9/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 115,800 shares of the Company’s common stock at an exercise price per share of $24.76, which was the closing price on June 8, 2021.
-
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
-
Arcus Biosciences Announces New Employment Inducement Grants - May 25, 2021
5/25/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eleven new employees options to purchase a total of 198,000 shares of the Company’s common stock at an exercise price per share of $24.55, which was the closing price on May 24, 2021.
-
Arcus Biosciences Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting
5/19/2021
In this first reported Phase 1b cohort, the etrumadenant-based combination was well tolerated with a composite overall response rate (ORR) of 41% in people previously treated for metastatic castrate-resistant prostate cancer (mCRPC) Etrumadenant is the first dual adenosine A 2a /A 2b receptor antagonist to demonstrate evidence of clinical activity in prostate cancer
-
Arcus Biosciences Announces New Employment Inducement Grants - May 11, 2021
5/11/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 126,000 shares of the Company’s common stock at an exercise price per share of $28.86, which was the closing price on May 10, 2021.
-
Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights
5/5/2021
Arcus Biosciences, Inc., (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the first quarter ended March 31, 2021 and provided operational highlights.
-
Arcus Biosciences Announces New Employment Inducement Grants - Apr 26, 2021
4/26/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 140,000 shares of the Company’s common stock at an exercise price per share of $35.77, which was the closing price on April 23, 2021.
-
Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
4/10/2021
Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting
-
Arcus Biosciences Announces New Employment Inducement Grants - Apr 09, 2021
4/9/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted twelve new employees options to purchase a total of 180,200 shares of the Company’s common stock at an exercise price per share of $30.90, which was the closing price on April 8, 2021.
-
Arcus Biosciences Announces New Employment Inducement Grants - Mar 24, 2021
3/24/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 157,300 shares of the Company’s common stock at an exercise price per share of $34.45, which was the closing price on March 23, 2021.
-
Arcus Biosciences Announces New Employment Inducement Grants - Mar 09, 2021
3/9/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 160,800 shares of the Company’s common stock at an exercise price per share of $31.49, which was the closing price on March 8, 2021.
-
Arcus Biosciences Announces New Employment Inducement Grants - Feb 25, 2021
2/25/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 31,400 shares of the Company’s common stock at an exercise price per share of $33.28, which was the closing price on February 23, 2021.
-
Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights
2/24/2021
- Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalimab’s advancement into a registrational study coupled with recent IND clearance for AB308, Arcus’s FcR-enabled anti-TIGIT antibody, reinforces Arcus’s position as a leader in the anti-TIGIT field - Promising early data in first-line metastatic pancreatic cancer for AB680, the first small-molecule CD73 inhibitor to enter clinical development,
-
Arcus Biosciences to Participate in Upcoming Investor Conferences
2/11/2021
Arcus Biosciences to Participate in Upcoming Investor Conferences
-
Arcus Biosciences Announces New Employment Inducement Grants - Feb 09, 2021
2/9/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 126,200 shares of the Company’s common stock at an exercise price per share of $41.39, which was the closing price on February 8, 2021.
-
Gilead Sciences to Increase Its Ownership In Arcus Biosciences
2/1/2021
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Gilead Sciences is increasing its ownership in Arcus to 19.5%, from approximately 13%, by purchasing 5,650,000 additional shares of Arcus’s common stock at a per share purchase price of $39.00.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 26, 2021
1/26/2021
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 165,300 shares of the Company’s common stock at an exercise price per share of $38.19, which was the closing price on January 25, 2021.
-
Clinical Catch-Up: January 11-15
1/18/2021
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news. -
Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
1/15/2021
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 12, 2021
1/12/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021.